Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited (NASDAQ: NVX, ASX: NVX) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer under Commission File Number 001-41208. On this SEC filings page, Stock Titan surfaces NOVONIX’s regulatory submissions, including Form 6-K current reports that transmit key corporate documents and market announcements.
NOVONIX’s recent Form 6-K filings reference items such as applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), notifications of issue or conversion of unquoted equity securities (Appendix 3G), changes in substantial holdings, and quarterly activities and cash flow reports. These documents provide detail on NOVONIX’s capital structure changes, equity issuance or cessation events, and operational and cash flow updates.
The company’s filings also identify its principal executive office in Brisbane, Queensland, Australia, and confirm its status as a foreign issuer with securities listed on NASDAQ. Through these filings, NOVONIX reports on matters connected to its battery materials and technology activities, including synthetic graphite manufacturing projects and related financing or governance actions disclosed to investors via attached exhibits.
On Stock Titan, NOVONIX filings are paired with AI-powered summaries that highlight the main points of each document in accessible language. Users can quickly see what type of filing NOVONIX has submitted, the nature of any security issuances or changes, and references to significant corporate announcements included as exhibits. Real-time updates from the EDGAR system, combined with these summaries, help readers navigate NOVONIX’s regulatory history and understand how its SEC reporting aligns with its broader business developments.
NOVONIX Ltd director Liveris Nicholas has reported his direct ownership of the company’s ordinary shares. As of 2026-03-16, he is shown as holding 459,090 ordinary shares directly. The filing does not show any new purchase or sale activity, only the reported ownership position.
NOVONIX Ltd director Tony Bellas filed an initial statement of beneficial ownership of ordinary shares. The filing reports 95,744 ordinary shares held directly. It also reports additional ordinary share holdings indirectly through corporations controlled by him, including 230,246 shares and 2,398,145 shares, reflecting his total reported equity stake as of the filing date.
Novonix Limited filed a Form 6-K reporting a change in director shareholdings via an attached ASX Appendix 3Y. The notice covers director Nicholas Liveris, whose interest is recorded as a direct holding following an on-market trade. After this change, he holds 459,090 ordinary shares in Novonix.
NOVONIX Limited filed a Form 6-K describing an exclusive access agreement to evaluate purchasing 17.5 acres of land directly adjacent to its Riverside anode materials facility in Chattanooga, Tennessee. The potential purchase price for the adjacent land is US$26.5 million, contingent on completing due diligence and deciding to proceed.
NOVONIX will pay US$100,000 for at least 150 days of exclusive due diligence and will assess whether the land can be re-zoned to heavy industrial use. The company states there is no certainty the transaction will proceed and will provide further updates under its continuous disclosure obligations.
NOVONIX Limited filed a Form 6-K reporting an Appendix 3Y notice to the ASX about a change in a director’s shareholding. The notice shows director Nicholas Liveris now has a relevant interest in 589,142 ordinary shares held directly following an on-market trade.
The filing confirms there was no trading during a closed period that required prior written clearance.
Novonix Limited filed a Form 6-K furnishing several Australian Appendix 3Y notices that update directors’ shareholdings after equity awards vested. For director Robert Natter, 120,594 share rights vested into 120,594 ordinary shares, reported as an indirect interest.
Director Anthony Bellas also saw 120,594 share rights vest into 120,594 ordinary shares, increasing his indirect holding via Loch to 2,398,145 ordinary shares, alongside other existing holdings. Directors Sharan Burrow, Ron Edmonds, Jean Oelwang and Nicholas Liveris reported higher ordinary share holdings following the issue of shares on vesting of share rights, with no trades during a closed period.
NOVONIX Limited reported the issue of 7,704,361 unquoted performance rights (ASX code NVXAD) under its employee incentive scheme. These rights are in an existing, unquoted class and are not intended to be listed on the ASX.
Following this grant, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside various unquoted securities including 25,092,989 performance rights in total, options, share rights, and convertible notes. The company confirms the issue was made under an exception in ASX Listing Rule 7.2, meaning separate security holder approval was not required.
NOVONIX Limited files its annual report on Form 20‑F, highlighting a capital-intensive growth plan, significant losses and substantial funding needs. The company reported a net loss of $84.5 million for 2025 and held $79.9 million in cash, cash equivalents and short‑term investments, alongside net current assets of $3.9 million. Management warns of material uncertainty about its ability to continue as a going concern.
NOVONIX is scaling synthetic graphite anode production at its Riverside facility in Chattanooga using proprietary furnace technology and long‑term offtake relationships with Panasonic Energy and PowerCo, but faces equipment delays, technology scale‑up risk and dependence on limited suppliers such as Harper and select needle coke producers. It has a $100 million DOE grant and a conditional DOE ATVM loan commitment of up to $754.8 million, both requiring significant cost sharing and strict compliance, plus a $103 million 48C tax credit allocation.
The company has entered a binding term sheet, subject to definitive agreements and conditions, to sell its Battery Technology Solutions business, which currently generates all revenue; after a divestiture, NOVONIX would have no revenue until its anode materials business scales. The filing details extensive risk factors spanning funding, customer concentration, graphite market dynamics, regulatory compliance and cybersecurity.
NOVONIX Limited filed an update announcing the timing of its 2026 Annual General Meeting. The AGM is scheduled for Wednesday, 15 April 2026 at 9:00am (AEST). The meeting details and agenda will be provided later in a formal Notice of Meeting sent to shareholders.
The company also set a cut-off for new board candidates. Nominations for persons to be considered for election as a director at the AGM must reach NOVONIX’s registered office by 5:00pm (AEST) on Wednesday, 25 February 2026. This notice complies with the company’s constitution and ASX Listing Rule 3.13.1.
NOVONIX LIMITED is arranging quotation on ASX for 127,021 new ordinary fully paid shares, issued on 30 January 2026 after conversion of performance rights under an employee incentive scheme. These shares are issued for non-cash consideration valued at AUD 0.39 per share.
The new shares form part of the existing NVX ordinary share class and will rank equally with all other quoted ordinary shares from their issue date. After this quotation, the company reports 859,902,420 NVX ordinary shares on issue, along with several unquoted classes including performance rights, options, share rights and convertible notes.